EHS
EHS

More Promising Tirzepatide Data; Continuous Glucose Monitoring Wins in Diabetes



(MedPage Today) — The investigational dual GIP and GLP-1 receptor agonist tirzepatide significantly reduced HbA1c levels and induced weight loss in patients with type 2 diabetes compared with insulin glargine in the SURPASS-4 trial, Eli Lilly…

Source link

EHS
Back to top button